Taoufik El Gnaoui

Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial

Nicolas Mounier, Taoufik El Gnaoui, H. Tilly et al. · Haematologica · 2013 · 169 citations · Full text

Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy

Taoufik El Gnaoui, Jehan Dupuis, Karim Belhadj et al. · Annals of Oncology · 2007 · 158 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Medicine +7

Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria

Jehan Dupuis, Emmanuel Itti, Alain Rahmouni et al. · Annals of Oncology · 2008 · 80 citations

Positron Emission Tomography, Lymphoid Neoplasia, Medicine +7

Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation

Clarisse Cazelles, Karim Belhadj, Hélène Vellemans et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2021 · 43 citations · Full text

Cell Therapy, R/r Dlbcl, Immunology +18

Clinical relevance of flow cytometric immunophenotyping of the cerebrospinal fluid in patients with diffuse large B-cell lymphoma

Ruth Álvarez, Jehan Dupuis, Anne Plonquet et al. · Annals of Oncology · 2011 · 40 citations

Lymphoid Neoplasia, Medicine, Cerebrospinal Fluid +10